Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Comorbid alcohol use and post-traumatic stress disorders: Pharmacotherapy with aldehyde dehydrogenase 2 inhibitors versus current agents.

Author information

Affiliations

  • 1. Baylor College of Medicine, Menninger Department of Psychiatry and Behavioral Sciences, 1977 Butler Blvd., Houston, TX 77030, United States of America.
      Authors
    • Morice CK 1
    (1 author)
  • 2. University of Texas Health Science Center at Houston, McGovern Medical School, Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, Behavioral and Biomedical Sciences Building, 1941 East Road, Houston, TX 77054, United States of America.
      Authors
    • Yammine L 2
    • Yoon J 2
    • Lane SD 2
    • Schmitz JM 2
    (4 authors)
  • 3. Baylor College of Medicine, Menninger Department of Psychiatry and Behavioral Sciences, 1977 Butler Blvd., Houston, TX 77030, United States of America; Baylor College of Medicine, Department of Pharmacology & Chemical Biology, One Baylor Plaza, BCM330, Houston, TX 77030, United States of America; Baylor College of Medicine, Department of Neuroscience, One Baylor Plaza, S640, Houston, TX 77030, United States of America; Baylor College of Medicine, Department of Pathology & Immunology, One Baylor Plaza, BCM315, Houston, TX 77030, United States of America.
      Authors
    • Kosten TR 3
    (1 author)
  • 4. University of California Los Angeles, David Geffen School of Medicine, Department of Psychiatry and Biobehavioral Sciences, Los Angeles, CA 90024, United States of America.
      Authors
    • De La Garza R 2nd 4
    (1 author)
  • 5. Baylor College of Medicine, Menninger Department of Psychiatry and Behavioral Sciences, 1977 Butler Blvd., Houston, TX 77030, United States of America; Baylor College of Medicine, Department of Pharmacology & Chemical Biology, One Baylor Plaza, BCM330, Houston, TX 77030, United States of America.
      Authors
    • Verrico CD 5
    (1 author)

ORCIDs linked to this article

Progress in Neuro-psychopharmacology & Biological Psychiatry, 05 Jan 2022, 115:110506
https://doi.org/10.1016/j.pnpbp.2021.110506 PMID: 34995723 

Review

Abstract 

The increased risk of alcohol use disorder (AUD) in individuals with post-traumatic stress disorder (PTSD) is well-documented. Compared to individuals with PTSD or AUD alone, those with co-existing PTSD and AUD exhibit greater symptom severity, poorer quality of life, and poorer treatment outcomes. Although the treatment of comorbid AUD is vital for the effective management of PTSD, there is a lack of evidence on how to best treat comorbid PTSD and AUD, and currently, there are no FDA-approved treatments for the PTSD-AUD comorbidity. The objective of this manuscript is to review the evidence of a promising target for treating the AUD-PTSD comorbidity. First, we summarize the epidemiological evidence and review the completed clinical studies that have tested pharmacotherapeutic approaches for co-existing AUD and PTSD. Next, we summarize the shared pathological factors between AUD and PTSD. We conclude by providing a rationale for selectively inhibiting aldehyde dehydrogenase-2 as a potential target to treat comorbid AUD in persons with PTSD.

Full text links 

Read article at publisher's site: https://doi.org/10.1016/j.pnpbp.2021.110506

Citations & impact 

Impact metrics

2
Citations
Jump to Citations

Alternative metrics

Altmetric item for https://www.altmetric.com/details/127133171
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/127133171

Article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.